key: cord-0681822-vyhv0g8t authors: Pang, Bo; Zhang, Junhua; Lee, Myeong Soo; Zheng, Wenke title: Enlightenment from Clinical Trials on Chinese Medicine for Coronavirus Disease 2019 (COVID-19) date: 2020-07-17 journal: Integr Med Res DOI: 10.1016/j.imr.2020.100481 sha: f1706130d157872402c5353454e9a59bc275e61b doc_id: 681822 cord_uid: vyhv0g8t nan (RCTs) were performed to provide evidence [7] . The controversy is mainly focused on: what is reliable clinical evidence? We aimed to clarify the questions of clinical evidence of TCM for COVID-19 from the viewpoint of evidence-based medicine and real-world study. According to our review, there were 121 registered protocols of TCM for COVID-19 identified from Chinese Clinical Trial Registry (www.chictr.org.cn) and ClinicalTrials.gov (up to June 30), 63 of them were RCTs. After comprehensive literature search, we found 26 published clinical controlled trials of TCM for COVID-19, and 11 of them were RCTs with 1301 patients. However, none of them were placebo-controlled and double-blinded RCTs. The types of patients, interventions and outcomes in different RCTs varied significantly. In addition, most of the published trials have not registered their protocols before case recruitment. Registered studies with protocols have not been completed, and published clinical trials were conducted in the absence of registered protocols, which reflected key problems in clinical trials of TCM for COVID-19. First, defects in methodology of clinical trials weakened the quality of evidence. Second, rigorously designed RCTs could not be completed due to the special environment dealing with COVID-19, which was a novel and highly infectious diseases. J o u r n a l P r e -p r o o f Knowledge of COVID-19 is limited for designing a good clinical trial protocol. COVID-19 is a novel infectious disease. Medical community knows only a little about the pathogenesis and evolution process of COVID-19, especially at the early stage of outbreak. As a sequence, it was difficult to design a scientific clinical trial protocol with clear patient inclusion criteria, appropriate treatment course and valuable outcomes. For example, the duration from onset to hospitalization of patients varied from several hours to more than one month. In addition, clinical symptoms and condition degree of patients were greatly heterogeneous and variable, which led to different treatment regime for individuals. Moreover, there was no consensus on clinical efficacy evaluation indicators at the beginning [8, 9] . Therefore, registered protocols commonly deviated from the real clinical situation. Most of the cases of COVID-19 were confirmed in the Hubei province. Doctors, nurses and other medical staffs have overworked in the circumstance with high risk of infection. This situation was no reliable for doctors to serve as investigators in a clinical trial. In addition, different medical wards were managed by different medical teams, which increased the difficulty of implementing an unified research program. The conditions for supporting a randomized double-blind placebo-controlled clinical trial on COVID-19 are not available as it is a novel infectious disease. There was no certain effective herbal drugs and therefore no prepared placebos. In addition, nearly no patient could agree to take any placebo because fear of death. The willingness of patients is a critical factor for the feasibility in a RCT. All of the patients wished to use potential effective treatments, especially herbal drugs which were helpful in patients' opinion. Therefore, in this case, it was virtually impossible to carry out patent informed, double-blind and placebo controlled RCTs. First, methodology and supporting condition for real-world studies should be strengthened. In response to the outbreak of novel disease, observational researches and RCTs are both essential to provide evidence for diagnosis and treatment. Therefore, all the accessible data of patients need to be collected. A simple, efficient and intelligent data management system is essential, which is different from commonly used electronic data capture system (EDC). Diagnostic information such as data of tongue and pulse, imaging examination, laboratory tests and patient-reported outcomes can be obtained and analyzed simultaneously. Other functions including randomization, allocation concealment, drug management and follow-up reminding should be merged into the platform. Intelligent data analysis is an important function, which can shorten the time of evidence production for early diagnosis and treatment. Low-level duplicated studies cannot generate high-level evidence, which not only leads to the waste of research resources, but also the failure of high-quality research. Therefore, related administrative departments should pay more attention to manage clinical trials during a novel disease outbreak as it would be helpful to conduct unified high quality studies to tackle the crucial problems in the condition of limited resources [10] . COVID-19): situation report-161 National Health Commission of the People's Republic of China traditional Chinese medicine plays a role in the prevention and treatment on novel coronavirus pneumonia More than 90 percent received th e treatment of traditional Chinese medicine Efficacy and Safety of Integ rated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-1 9): a systematic review and meta-analysis Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials China is promoting coronavirus treatments based on unproven traditional med icines Core Outcome Set for Outcomes and related issues of clinical trials for novel coronavirus pneumonia Insight into current clinical research of Chinese medicine on COVID-19 Real-World Evidence -What Is It and What Can It Tell Us? This research was funded by COVID-19 Prevention and Treatment Drug Development Program (2020-CMKYGG-03). Not applicable.This research did not require an ethical approval as it does not involve any human or animal experiment. Not applicable.The data will be made available upon request.